Want to see LNTH full AI Analyst Report?
LNTH Stock Chart & Stats
$100.87
$3.21(3.06%)
At close: 4:00 PM EDT
$100.87
$3.21(3.06%)
Day’s Range― - ―
52-Week Range$50.16 - $111.86
Previous Close$117
Volume1.07M
Average Volume (3M)954.58K
Market Cap
$6.52B
Enterprise Value$7.52B
Total Cash (Recent Filing)$593.30M
Total Debt (Recent Filing)$624.96M
Price to Earnings (P/E)23.8
Beta0.36
Next Earnings
Oct 29, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,299,870
10 Day Avg. Volume942,125
30 Day Avg. Volume954,583
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue4.83
Enterprise Value/Gross Profit8.04
Enterprise Value/Ebitda15.96
Forecast
1Y Price Target
$104.48Price Target Upside3.58% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)5.41
Revenue Forecast (FY)$1.48B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow indicates that Lantheus converts its business activity into funding reliably. This supports investment in radiopharmaceutical capacity, commercial expansion, and strategic initiatives while reducing dependence on external financing over the next several quarters.
Revenue Re-acceleration And Healthy MarginsThe sharp revenue re-acceleration, combined with strong gross and operating margins, suggests meaningful demand and operating leverage across Lantheus’ portfolio. If maintained, this performance can strengthen earnings capacity and provide resources to expand key imaging franchises.
Shareholder Approval Supports Strategic CombinationShareholder approval removes a major corporate hurdle and supports Curium’s plan to combine Lantheus’ radiodiagnostics platform with broader radiopharmaceutical capabilities. The transaction could improve strategic scale and commercial reach, subject to remaining regulatory and closing conditions.
Bears Say
Bottom-line Earnings VolatilityDeclining net income despite healthy gross and operating margins indicates pressure below the operating line and less consistent bottom-line performance. This volatility can complicate planning, reduce confidence in near-term earnings conversion, and limit the predictability of shareholder returns.
Moderate Debt Remains On Balance SheetLeverage has improved substantially, but the remaining debt burden means Lantheus is not operating from a net-cash position. Interest obligations and refinancing needs could reduce flexibility for investment or strategic execution if profitability weakens over the next several quarters.
Merger Remains Exposed To Regulatory And CVR Execution RiskThe ownership transition still depends on antitrust approval and other closing conditions, creating execution uncertainty despite shareholder support. In addition, milestone-based CVR value depends on future commercial performance, so the transaction’s full economic benefit is not assured.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $50.16 and its highest was $111.86 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $6.52B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Aug 06, 2026. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.304 by $0.246.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.26.
How many shares outstanding does Lantheus have?
Lantheus has 65,299,870 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.55 in its last earnings report, beating expectations of $1.304. Following the earnings report the stock price went down -0.424%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$104.48 (3.58% Upside)
$104.48 (3.58% Upside)
Blogger Sentiment
Neutral
LNTH Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 336.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.36%
12-Months-Change
Fundamentals
Return on Equity
23.27%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lantheus
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
LNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$104.48
▲(3.58% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
HUTCHMED
―
Eton Pharmaceuticals
―
Ownership Overview
1.82% Insiders
34.73% Mutual Funds
2.07% Other Institutional Investors
30.92% Public Companies and
Individual Investors